Enzalutamide (CAS 915087-33-1) – Selective Androgen Receptor Antagonist Anticancer API

Enzalutamide (CAS 915087-33-1) is a high-purity pharmaceutical API classified as a selective androgen receptor antagonist, featuring a substituted anilide molecular structure with high affinity for androgen receptors. Unlike non-selective anti-androgens, it acts through a dual mechanism—binding to androgen receptors to block ligand activation and inhibiting receptor nuclear translocation—effectively suppressing prostate cancer cell growth and progression. This premium API exhibits excellent oral bioavailability and tissue-specific targeting, minimizing off-target effects on other hormone systems.

It caters to the core needs of oncology drug manufacturers, prostate cancer research institutions, and clinical supply chains. Specifically developed for treating metastatic castration-resistant prostate cancer (mCRPC), it aligns with the demand for targeted, well-tolerated therapies for advanced prostate cancer. Produced under strict GMP standards, each batch undergoes rigorous purity and potency testing to meet international pharmacopoeia requirements, ensuring consistency for clinical use. For businesses prioritizing precision oncology solutions, this Enzalutamide API serves as a critical raw material for advancing prostate cancer therapeutic development.